Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib
F.S. Gillesberg(Aarhus University), Joachim Høg Mortensen(Nordic Bioscience (Denmark)), Peder Frederiksen(Frederiksberg Hospital), Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Martin Pehrsson(Nordic Bioscience (Denmark)), M.A. Karsdal(Nordic Bioscience (Denmark)), Satoshi Kubo(University of Occupational and Environmental Health Japan), Anne‐Christine Bay‐Jensen(Nordic Bioscience (Denmark)), Tue Wenzel Kragstrup(Aarhus University), Bent Deleuran(Aarhus University)
Cited by 31
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413